PTEN is altered in 8.13% of malignant solid tumor patients [3].

PTEN is an inclusion criterion in 48 clinical trials for malignant solid tumor, of which 36 are open and 12 are closed. Of the trials that contain PTEN status and malignant solid tumor as inclusion criteria, 20 are phase 1 (12 open), 11 are phase 1/phase 2 (8 open), 16 are phase 2 (15 open), and 1 is phase 4 (1 open) [4].

PTEN is altered in 7.35% of breast carcinoma patients [3].

PTEN is an inclusion criterion in 33 clinical trials for breast carcinoma, of which 27 are open and 6 are closed. Of the trials that contain PTEN status and breast carcinoma as inclusion criteria, 10 are phase 1 (7 open), 6 are phase 1/phase 2 (4 open), 14 are phase 2 (13 open), and 3 are phase 3 (3 open) [4].

PTEN is altered in 17.77% of prostate carcinoma patients [3].

PTEN is an inclusion criterion in 15 clinical trials for prostate carcinoma, of which 9 are open and 6 are closed. Of the trials that contain PTEN status and prostate carcinoma as inclusion criteria, 5 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 2 are phase 3 (2 open) [4].

PTEN is altered in 17.72% of prostate adenocarcinoma patients [3].

PTEN is an inclusion criterion in 12 clinical trials for prostate adenocarcinoma, of which 10 are open and 2 are closed. Of the trials that contain PTEN status and prostate adenocarcinoma as inclusion criteria, 10 are phase 2 (8 open) and 2 are phase 3 (2 open) [4].

PTEN is altered in 4.06% of ovarian carcinoma patients [3].

PTEN is an inclusion criterion in 12 clinical trials for ovarian carcinoma, of which 7 are open and 5 are closed. Of the trials that contain PTEN status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 1 is phase 3 (0 open) [4].

PTEN is altered in 3.33% of non-small cell lung carcinoma patients [3].

PTEN is an inclusion criterion in 12 clinical trials for non-small cell lung carcinoma, of which 6 are open and 6 are closed. Of the trials that contain PTEN status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open), 6 are phase 1/phase 2 (3 open), and 4 are phase 2 (3 open) [4].

PTEN is altered in 4.89% of medulloblastoma patients [3].

PTEN is an inclusion criterion in 9 clinical trials for medulloblastoma, of which 9 are open and 0 are closed. Of the trials that contain PTEN status and medulloblastoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [4].

PTEN is altered in 48.03% of endometrial carcinoma patients [3].

PTEN is an inclusion criterion in 8 clinical trials for endometrial carcinoma, of which 6 are open and 2 are closed. Of the trials that contain PTEN status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [4].

PTEN is altered in 10.72% of small cell lung carcinoma patients [3].

PTEN is an inclusion criterion in 7 clinical trials for small cell lung carcinoma, of which 5 are open and 2 are closed. Of the trials that contain PTEN status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (1 open) [4].

PTEN is altered in 6.31% of head and neck squamous cell carcinoma patients [3].

PTEN is an inclusion criterion in 7 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 4 are closed. Of the trials that contain PTEN status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (1 open) [4].

PTEN is altered in 8.7% of primary peritoneal carcinoma patients [3].

PTEN is an inclusion criterion in 6 clinical trials for primary peritoneal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain PTEN status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [4].

PTEN is altered in 8.17% of melanoma patients [3].

PTEN is an inclusion criterion in 6 clinical trials for melanoma, of which 4 are open and 2 are closed. Of the trials that contain PTEN status and melanoma as inclusion criteria, 2 are phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [4].

PTEN is altered in 6.26% of colorectal carcinoma patients [3].

PTEN is an inclusion criterion in 6 clinical trials for colorectal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain PTEN status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [4].

PTEN is altered in 9.73% of squamous cell lung carcinoma patients [3].

PTEN is an inclusion criterion in 5 clinical trials for squamous cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PTEN status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (0 open), and 1 is no phase specified (1 open) [4].

PTEN is altered in 1.59% of fallopian tube carcinoma patients [3].

PTEN is an inclusion criterion in 5 clinical trials for fallopian tube carcinoma, of which 2 are open and 3 are closed. Of the trials that contain PTEN status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [4].

PTEN is altered in 4.24% of gastric carcinoma patients [3].

PTEN is an inclusion criterion in 4 clinical trials for gastric carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [4].

PTEN is altered in 3.71% of urothelial carcinoma patients [3].

PTEN is an inclusion criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

PTEN is altered in 4.16% of adenocarcinoma of the gastroesophageal junction patients [3].

PTEN is an inclusion criterion in 4 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [4].

PTEN is altered in 3.05% of non-hodgkin lymphoma patients [3].

PTEN is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

PTEN is altered in 1.1% of pancreatic adenocarcinoma patients [3].

PTEN is an inclusion criterion in 4 clinical trials for pancreatic adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

PTEN is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain PTEN status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

PTEN is altered in 37.66% of glioblastoma patients [3].

PTEN is an inclusion criterion in 3 clinical trials for glioblastoma, of which 1 is open and 2 are closed. Of the trials that contain PTEN status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

PTEN is altered in 3.82% of osteosarcoma patients [3].

PTEN is an inclusion criterion in 3 clinical trials for osteosarcoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

PTEN is altered in 4.28% of gastric adenocarcinoma patients [3].

PTEN is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 1 is open and 2 are closed. Of the trials that contain PTEN status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (1 open) [4].

PTEN is altered in 4.51% of soft tissue sarcoma patients [3].

PTEN is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

PTEN is altered in 29.52% of malignant glioma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [4].

PTEN is altered in 9.75% of leiomyosarcoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for leiomyosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and leiomyosarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

PTEN is altered in 8.99% of oropharyngeal squamous cell carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for oropharyngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is altered in 7.58% of cancer patients [3].

PTEN is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain PTEN status and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 1 is phase 1 (1 open) [4].

PTEN is altered in 5.0% of desmoplastic/nodular medulloblastoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is altered in 5.65% of renal cell carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

PTEN is altered in 5.57% of clear cell renal cell carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is altered in 5.25% of head and neck carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is altered in 6.38% of undifferentiated pleomorphic sarcoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for undifferentiated pleomorphic sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is altered in 3.53% of central nervous system embryonal neoplasm patients [3].

PTEN is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is altered in 3.12% of gastrointestinal stromal tumor patients [3].

PTEN is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is altered in 2.65% of chondrosarcoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for chondrosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is altered in 2.48% of esophageal carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

PTEN is altered in 3.02% of hepatocellular carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is altered in 1.54% of Ewing sarcoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 1.11% of pancreatic carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is altered in 0.31% of myeloid neoplasm patients [3].

PTEN is an inclusion criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [4].

PTEN is altered in 26.87% of diffuse glioma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 21.97% of glioma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 20.51% of malignant central nervous system neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 16.9% of myxoid liposarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for myxoid liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and myxoid liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 14.29% of breast lobular carcinoma in situ patients [3].

PTEN is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

PTEN is altered in 13.86% of high-grade glioma, NOS patients [3].

PTEN is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 16.67% of pleomorphic rhabdomyosarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for pleomorphic rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pleomorphic rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 8.58% of anaplastic astrocytoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 9.52% of hypopharyngeal squamous cell carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 8.57% of pancreatic ductal adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTEN status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

PTEN is altered in 7.3% of cervical carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 7.67% of colon carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for colon carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and colon carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

PTEN is altered in 8.24% of laryngeal squamous cell carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 7.11% of breast adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and breast adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

PTEN is altered in 6.23% of colorectal adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 6.22% of malignant intestinal neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 7.5% of pleomorphic liposarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for pleomorphic liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pleomorphic liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 4.55% of myxofibrosarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and myxofibrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 4.86% of malignant small intestinal neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 4.59% of thyroid gland carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 4.51% of malignant ovarian epithelial tumor patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 4.34% of oral cavity carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 4.34% of oral cavity squamous cell carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 4.18% of liposarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 3.17% of anaplastic ependymoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 4.24% of malignant gastric neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 3.71% of rectal carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and rectal carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

PTEN is altered in 2.48% of angiosarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for angiosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and angiosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 4.41% of rhabdomyosarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 3.74% of malignant mesothelioma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 4.26% of malignant peripheral nerve sheath tumor patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 3.29% of malignant esophagogastric neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 2.22% of anaplastic oligodendroglioma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 2.58% of biliary tract carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 2.56% of esophageal adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 2.14% of ampulla of vater carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 1.96% of bile duct adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is altered in 1.96% of cholangiocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 2.99% of B-cell non-hodgkin lymphoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 2.71% of high grade ovarian serous adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 2.68% of lymphoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 1.08% of peritoneal mesothelioma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 2.02% of hematologic and lymphocytic disorder patients [3].

PTEN is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 1.96% of thymic carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 1.53% of follicular lymphoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and follicular lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 0.74% of histiocytic and dendritic cell neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 1.05% of hematopoietic and lymphoid system neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 1.07% of hematopoietic and lymphoid malignancy patients [3].

PTEN is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 0.53% of neuroblastoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is altered in 0.24% of acute myeloid leukemia patients [3].

PTEN is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is altered in 0.11% of myelodysplastic syndromes patients [3].

PTEN is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for bannayan syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and bannayan syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for cowden syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and cowden syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for extraskeletal osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and extraskeletal osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for hereditary breast and ovarian cancer syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hereditary breast and ovarian cancer syndrome as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for proteus syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and proteus syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PTEN status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [4].